IASLC WCLC 2021: Durvalumab-Tremelimumab Plus Chemotherapy a Potential New First-Line Treatment for Metastatic Non–Small Cell Lung Cancer
The addition of durvalumab with or without tremelimumab to chemotherapy improved outcomes over chemotherapy alone
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.